Sac-TMT shows 51% PFS benefit in first-line, PD-L1-negative NSCLC in a China phase 3 trial that could help Merck close a high-stakes gap in its global program for the Kelun-partnered TROP2 ADC. #ESMO26 https://www.fiercepharma.com/pharma/merck-kelun-workhorse-adc-posts-major-tumor-progression-benefit-pd-l1-negative-nsclc